Responses
Clinical/translational cancer immunotherapy
Original research
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
Compose a Response to This Article
Other responses
No responses have been published for this article.